JACKSONVILLE, Fla. (AP) — JACKSONVILLE, Fla. (AP) — Fidelity National Information Services Inc. (FIS) on Tuesday reported second-quarter profit of $231 million. On a per-share basis, the Jacksonville, ...
Shares of Fidelity National Information Services Inc. FIS slid 1.73% to $46.00 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX ...
Fidelity National Financial (FNF) is appealing a federal judge’s decision to uphold the Financial Crimes Enforcement Network (FinCEN) Anti-Money Laundering Regulations for Residential Real Estate ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Fidelity National Financial is upgraded to "Buy" after a 25% share price decline, offering 13% upside and a secure 4.4% dividend yield. I estimate FNF’s fair value at $53 per share, factoring in its ...
Former Compass Title & Escrow executive tapped to scale agency operations, drive efficiency, and expand tech-enabled growth across FNF’s national network Fidelity National Financial (FNF) appointed ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Mike Nolan: Thank you, Lisa, and good morning. The fourth quarter results rounded out an excellent year for our Title and F&G business both in terms of results and execution. Our Title business ...
Fidelity National Information Services (FIS-3.42%) stock plummeted to a 52-week low on Tuesday, dropping some 4% on the day to around $60.60 per share. For a company that is one of the few dominant ...
Fidelity National Financial reported strong Q3 results, beating earnings estimates and announcing a special stock distribution of F&G shares to investors. Title business performance improved with 13% ...
Phase 2b findings demonstrate improved 2-year survival outcomes with OST-HER2 compared with historical control data. Treatment with OST-HER2 (OST31-164) produced a statistically significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results